Literature DB >> 11704996

Pathogenesis of ophthalmopathy in autoimmune thyroid disease.

A E Heufelder1.   

Abstract

What causes GO is still a mystery, but the disease process results from a complex interplay of genetic and environmental factors. Genes such as those for HLA genes may determine a patient's susceptibility to the disease and its severity, but environmental factors, often unknown, may determine its course. Once established, the chronic inflammatory process within the orbital tissues appears to take on a momentum of its own. Given our current state of knowledge, the following working scheme for the pathogenesis of GO can be proposed (Fig. 1): On the background of a permissive immunogenetic milieu, circulating T cells in patients with GD, directed against certain antigens on thyroid follicular cells, recognize antigenic epitopes that are shared by tissues contained in the orbital space. Of the cell types residing in these tissues, preadipocytes and fibroblasts, most likely act as target and effector cells of the orbital immune process, respectively. This includes preadipocyte fibroblasts present in the perimysium of extraocular muscles, which do not appear to be immunologically different from those located in the orbital connective tissue. Orbital preadipocyte fibroblasts may be stimulated by unknown circulating or locally produced factors to differentiate into mature adipocytes that express increased levels of TSHr. How autoreactive T cells escape deletion and control by the immune system and come to be directed against a self-antigen presented by cells residing in the thyroid gland and extrathyroidal locations, is still unknown. Proliferation and expansion of autoreactive T cell clones may be due to mimicry of a host antigen by a microorganism, but this remains speculative. T cell recruitment into the orbital tissues is facilitated by certain chemokines and cytokines, which help to attract T cells by stimulating the expression of certain adhesion molecules (e.g., ICAM-1, VCAM-1, CD44) in vascular endothelium and connective tissue cells. These adhesion receptors are known to also play an important costimulatory role by activating T cells and facilitating antigen recognition, which amplifies the cellular immune process. Analysis of variable region genes of T cell antigen receptors in orbital T cells of patients with active GO has revealed their restricted TcR V gene usage, suggesting that antigen-driven selection and/or expansion of specific T cells may occur early in the evolution of GO. T cells and macrophages populating the orbital space are known to synthesize and release a [figure: see text] number of cytokines (most likely a Th1-type spectrum) into the surrounding tissue. Cytokines, oxygen free radicals and fibrogenic growth factors, released both from infiltrating inflammatory and residential cells, act upon orbital preadipocytes in a paracrine and autocrine manner to stimulate adipogenesis, fibroblast proliferation, glycosaminoglycan synthesis, and the expression of immunomodulatory molecules. Smoking, a well-known aggravating factor in GO, may aggravate tissue hypoxia and exert important immunomodulatory effects. The long held hypothesis of a thyroid cross-reactive antigen within the orbital tissues has recently gained significant support by an animal model of GO, and by in vitro and ex vivo studies. If confirmed in immunological studies, these data may well explain the localized infiltration of the orbital tissues by autoreactive lymphocytes that share intriguing molecular features with intrathyroidal lymphocytes. Local release of particular cytokines, TSHr-directed antibodies, or other factors might further enhance adipogenesis, glycosaminoglycan synthesis and expression of immunomodulatory proteins within the orbit. Other factors, including inflammatory cytokines, might act as counterbalancing inhibitors of these effects. However, if the net effect of these changes is to increase the volume of the fatty connective tissues within the orbit, then proptosis, extraocular muscle dysfunction, and periorbital congestion will ensue. Whether this hypothetical sequence of events will finally explain the involvement of the orbit in GD is unknown. Future studies will be aimed at identifying factors that might modulate adipogenesis in orbital cells and clarifying the link between adipogenesis and TSHr expression in the orbit. Taken together, a number of important details in the complex pathogenesis of GO have been resolved in recent years, but many challenges are still ahead. Elucidation of the primary antigen and how it is recognized by the immune system will be key issues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11704996     DOI: 10.1023/a:1010020621687

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  73 in total

1.  Association between Graves' ophthalmopathy and smoking.

Authors:  B Shine; P Fells; O M Edwards; A P Weetman
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

2.  Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey.

Authors:  A P Weetman; W M Wiersinga
Journal:  Clin Endocrinol (Oxf)       Date:  1998-07       Impact factor: 3.478

3.  Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital radiotherapy.

Authors:  L C Hofbauer; T Mühlberg; A König; G Heufelder; H D Schworm; A E Heufelder
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

4.  Transfer of thyroiditis, with syngeneic spleen cells sensitized with the human thyrotropin receptor, to naive BALB/c and NOD mice.

Authors:  S Costagliola; M C Many; M Stalmans-Falys; G Vassart; M Ludgate
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

5.  A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype.

Authors:  H Allannic; R Fauchet; Y Lorcy; M Gueguen; A M Le Guerrier; B Genetet
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

6.  Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin.

Authors:  M Tellez; J Cooper; C Edmonds
Journal:  Clin Endocrinol (Oxf)       Date:  1992-03       Impact factor: 3.478

7.  Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.

Authors:  M F Prummel; W M Wiersinga; M P Mourits; L Koornneef; A Berghout; R van der Gaag
Journal:  Arch Intern Med       Date:  1990-05

8.  TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema.

Authors:  W Stadlmayr; C Spitzweg; A M Bichlmair; A E Heufelder
Journal:  Thyroid       Date:  1997-02       Impact factor: 6.568

9.  Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy.

Authors:  A E Heufelder; R S Bahn
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

10.  Cell surface localization of a 72 kilodalton heat shock protein in retroocular fibroblasts from patients with Graves' ophthalmopathy.

Authors:  A E Heufelder; B E Wenzel; R S Bahn
Journal:  J Clin Endocrinol Metab       Date:  1992-04       Impact factor: 5.958

View more
  16 in total

1.  Genetics of thyroid-associated ophthalmopathy: a play in search of a cast of characters.

Authors:  N R Farid; M Marga
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

Review 2.  New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors:  R A Ajjan; A P Weetman
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

3.  Histopathologic analysis of palpebral conjunctiva in thyroid-related orbitopathy (an american ophthalmological society thesis).

Authors:  Don O Kikkawa
Journal:  Trans Am Ophthalmol Soc       Date:  2010-12

4.  Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.

Authors:  David B Granet; Nickisa Hodgson; Kyle J Godfrey; Ricardo Ventura; Don O Kikkawa; Leah Levi; Michael Kinori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-10       Impact factor: 3.117

5.  [Protrusio bulbi].

Authors:  B Sadowski; R Wöhrle; N Wöhrle; K Helmke
Journal:  Ophthalmologe       Date:  2006-09       Impact factor: 1.059

6.  Surgical Outcomes of Balanced Deep Lateral and Medial Orbital Wall Decompression in Korean Population: Clinical and Computed Tomography-based Analysis.

Authors:  Sang Uk Choi; Kyoung Woo Kim; Jeong Kyu Lee
Journal:  Korean J Ophthalmol       Date:  2016-03-25

Review 7.  Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy.

Authors:  Meritxell Arenas; Sebastià Sabater; Pedro Lara Jiménez; Àngels Rovirosa; Albert Biete; Victoria Linares; Montse Belles; Julià Panés
Journal:  Rep Pract Oncol Radiother       Date:  2016-03-04

Review 8.  Orbital inflammation.

Authors:  Kimberly P Cockerham; Sang H Hong; Ellen E Browne
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

9.  Graves' ophthalmopathy and atrophic thyroiditis: a case report.

Authors:  G Tamagno; E De Carlo; C Betterle; G Murialdo
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

10.  [Graves disease. An important differential diagnostic consideration for systemic lupus erythematosus].

Authors:  F Meiss; M Fischer; J Hädecke; M Knorrn; W C Marsch
Journal:  Hautarzt       Date:  2004-05       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.